Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinibMax J. Gordon, Alexey V. Danilov, Sudhir Manda et al.|Cancer|2018Cited by 86
The Selective Syk Inhibitor P505-15 (PRT062607) Inhibits B Cell Signaling and Function In Vitro and In Vivo and Augments the Activity of Fludarabine in Chronic Lymphocytic LeukemiaStephen E. Spurgeon, Marc Loriaux|Journal of Pharmacology and Experimental Therapeutics|2012Cited by 53
Diminished humoral and cellular responses to SARS-CoV-2 vaccines in patients with chronic lymphocytic leukemiaChaitra Ujjani, Philip A. Thompson, Ted Gooley et al.|Blood Advances|2022Cited by 12
Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLLAdam S. Kittai, Jennifer A. Woyach, Ying Huang et al.|Blood Cancer Journal|2025Cited by 12